Update on acellular pertussis vaccine efficacy through September 11, 1988

Two consecutive randomized controlled pertussis booster trials in children initially vaccinated in infancy with an acellular vaccine: The first with a five-component Tdap vaccine to 5-year olds and the second with five- or monocomponent Tdap vaccines at age 14-15 years.

Vaccine·2015

Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012.

Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2014

A review of the evidence to inform pneumococcal vaccine recommendations for risk groups aged 2 years and older.

Epidemiology and infection·2014

Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A.

Sleep medicine·2013

Evidence of protective effect of BCG vaccination in persons at low risk of tuberculosis in Nordic countries.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2009

Extensive transmission of an isoniazid-resistant strain of Mycobacterium tuberculosis in Sweden.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2008